secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2022-05-18T23:59:59+00:00
Accession:  0001193125-22-154021
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Vertex shareholders elect 11 directors, approve stock plan amendment adding 13.5M shares
--------------------------------------------------------------------------------

- All 11 director nominees elected, with Reshma Kewalramani receiving 218.7M votes for.
- Ratification of Ernst & Young as auditor for FY2022 passed with 177.8M for, 51.9M against.
- Advisory say-on-pay approved, 202.2M for vs 16.1M against.
- Amendment to 2013 Stock and Option Plan adding 13.5M shares authorized for issuance approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000119312522154021/0001193125-22-154021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000119312522154021/d272923d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-154021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer